3.1 All information furnished by both Parties (“Confidential Information”) pursuant to this Agreement, to Sponsor, Institution/Investigator, shall be treated by Sponsor and Institution/Investigator as confidential for a period of five (5) years after termination of this Agreement. Sponsor and Institution/Investigator shall i) hold the Confidential Information in confidence and not disclose or permit it to be made available to any third party, without the other Party’s prior written consent, ii) only use the Confidential Information for the Study, iii) take any reasonable steps to the effect that each person employed at the Sponsor or Institution to whom disclosure of the Confidential Information is made will be under the same confidentiality obligations as applies for Sponsor or Institution under this Agreement, and iv) upon written demand from Sponsor either at Sponsor’s expense to return the Confidential Information and any copies of it or to confirm in writing that it has been destroyed. However, Institution/Investigator may keep one copy for documentation purposes.

3.2 The foregoing Section 3.1 does not apply to any of the Confidential Information which Institution/Investigator can show i) is already lawfully known to Institution/Investigator at the date it was disclosed to it by Sponsor and is or becomes free of restriction on the disclosure or use in question, or ii) is or becomes generally known or freely available to the public (except by reason of any breach by Institution/Investigator of its obligations hereunder), or iii) is disclosed to Institution/Investigator, free of restriction on the disclosure or use in question, by a third party who was entitled to make such unrestricted disclosure, or iv) is independently developed by Institution/Investigator, or v) is disclosed, retained or maintained by law or any regulatory or government authority.

### 4. Publication

4.1 The Parties recognize that Danish law places an obligation on hospitals carrying out health and social care research to publish their work. The Parties agree that this Section 4 should be interpreted in light of such obligation. 4.2 Following completion of the entire Study at all sites, Sponsor shall use all reasonable endeavors to ensure the appropriate publication or other dissemination of the conclusions of the Study, and Institution/Investigator for such Study shall not publish data/results derived from the individual institution site until the combined results from the entire Study has been published in a joint, multi-centre publication, cf. the Protocol. If such a multi- centre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after the Sponsor confirms there will be no multi-centre clinical trial publication, Institution/Investigator may publish the data/results from the Institution individually in accordance with this Section 5.

4.3 Site investigators authorships and the order of authorship for the Sponsors team will be as described in the protocol.

4.4 If Institution/Investigator wish to publish data/results from the Study, a copy of the manuscript must be provided to the Sponsor for review at least thirty (30) days prior to submission for publication, presentation or release. The Sponsor and Investigator will arrange expedited reviews for abstracts, poster presentations or other materials. Within this 30 day period, the Sponsor shall review such proposed publication or presentation or release to determine whether it contains any Confidential Information of Sponsor (as defined in Section 3), or whether Sponsor desires to file patent applications on subject matter contained therein. Upon receiving any notification from Sponsor requesting deletion of Confidential Information of Sponsor, or requesting a delay in publication to allow the filing of patent applications before publication or release, Investigator shall take the requested action; provided however, that any delay in publication shall not exceed ninety (90) days

Page 5